Christopher Haqq

Insider Reports History

Location
Brisbane, CA
Signature
/s/ Christopher Haqq
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Haqq:

Company Role Class Num Shares Value Price $ Report Date Ownership
Surrozen, Inc./DE Former Director Common Stock 30,000 $11,400 $0.3800 11 Aug 2021 Direct
Elicio Therapeutics, Inc. Executive Vice President, Head of R&D and Chief Medical Officer Stock Option (Right to Buy) 44,000 03 Feb 2025 Direct
Surrozen, Inc./DE Former Director Class B Ordinary Shares 0 11 Aug 2021 Direct

Insider Reports Filed by Christopher Haqq

Symbol Company Period Transactions Value $ Form Type Role Filing Time
ELTX Elicio Therapeutics, Inc. 03 Feb 2025 1 $0 4 Executive Vice President, Head of R&D and Chief Medical Officer 04 Feb 2025, 16:10
ELTX Elicio Therapeutics, Inc. 30 Sep 2024 1 $0 4 Title: Executive Vice President, Head of R&D and Chief Medical Officer 02 Oct 2024, 16:12
ELTX Elicio Therapeutics, Inc. 01 Feb 2024 1 $0 4 Title: Executive Vice President, Head of R&D and Chief Medical Officer 05 Feb 2024, 06:01
ELTX Elicio Therapeutics, Inc. 01 Jun 2023 0 $0 3 Exhibit 24.1 - Power of Attorney. Title: Executive Vice President, Head of R&D and Chief Medical Officer 12 Jun 2023, 17:12
SRZN Surrozen, Inc./DE 11 Aug 2021 2 $0 4 Former Director 13 Aug 2021, 19:38